Glomerulonephritis - Pipeline Review, H2 2018 - Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

September 21, 2018

DUBLIN--(BUSINESS WIRE)--Sep 21, 2018--The “Glomerulonephritis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Glomerulonephritis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 16, 4, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

IntroductionGlomerulonephritis - OverviewGlomerulonephritis - Therapeutics DevelopmentGlomerulonephritis - Therapeutics AssessmentGlomerulonephritis - Companies Involved in Therapeutics DevelopmentGlomerulonephritis - Drug ProfilesGlomerulonephritis - Dormant ProjectsGlomerulonephritis - Discontinued ProductsGlomerulonephritis - Product Development MilestonesAppendix

Companies Mentioned

Achillion Pharmaceuticals IncAduro BioTech IncAlexion Pharmaceuticals IncAlgomedix IncAmyndas Pharmaceuticals LLCApellis Pharmaceuticals IncAurinia Pharmaceuticals IncAvexxin ASBiogen IncBristol-Myers Squibb CoCalliditas Therapeutics ABCellmid LtdChemoCentryx IncComplexa IncCytodesign IncDimerix Bioscience Pty LtdErgon Pharmaceuticals LLCGoldfinch Biopharma IncHanAll Biopharma Co LtdKyowa Hakko Kirin Co LtdMerck KGaANovartis AGOmeros CorpOraxion Therapeutics IncPfizer IncPolyneuron Pharmaceuticals AGRa Pharmaceuticals IncReata Pharmaceuticals IncRetrophin IncRigel Pharmaceuticals IncSarfez Pharmaceuticals IncShire PlcSujana Biotech, LLCVariant Pharmaceuticals IncVisterra IncFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ls7kng/glomerulonephritis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180921005552/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/21/2018 03:12 PM/DISC: 09/21/2018 03:12 PM


Update hourly